Budget impact of metformin 1g immediate release tablet prescribing

The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g IR tablets across the ICSs in the North East & Yorkshire region and Greater Manchester.

This publication was updated in May 2024 – First published in February 2023

NHS Medicines Optimisation Opportunities Dashboard 2023-24

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.

The RDTC has developed a Northern regions dashboard to highlight the current position of the ICBs across the North of England in relation to these 16 priorities. It will incorporate the metrics that are being developed nationally, but also include metrics which are designed to support medicines optimisation opportunities across the North.

Metrics within this dashboard continue to be developed and updates will be communicated out to stakeholders as they happen. Data is now provided within the report at SICBL level where available.

The dashboard is provided to NHS colleagues only, please do not share outside the NHS.

If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.

We have also developed 9 individual reports covering 12 of the medicines optimisation opportunity topics which can be found on their dedicated pages:

Shared care protocol – hydroxycarbamide in adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.2

Last updated: 15th May 2024

Prescribing Update Newsletter – February 2024

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition focuses on the added features and updates to the RDTC Medicines Optimisation Opportunities Dashboard, and the updated version of the Inhaler Carbon Impact Assessment Tool. It also includes information on some key medicines availability issues, the dates of our upcoming demo and Q&A sessions on RDTC reports, publications, and resources, and another in the series of “Meet the Team” where you can get to know the people behind the work we do.

View the preview below on desktop, or click here to download a copy

Monthly formulary amendments – February 2024

Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines.  This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.

This edition covers guidance and alerts published in February 2024.

It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.

This information is produced for use by NHS healthcare professionals and RDTC stakeholders.

Monthly Horizon Scanning Report – February 2024

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals. 

Shared care protocol – ciclosporin (oral) for adults (non-transplant)

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.0

Last updated: 14th February 2024

Shared care protocol – hydroxychloroquine for adults

This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.

These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.

Update information

Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.

Current version: v1.0

Last updated: 14th December 2023

Problematic Polypharmacy:  Prescribing Cascades Evidence Evaluation

Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve. PPHs use prescribing data, biomedical literature and other data sources to provide new insights.

Problematic polypharmacy is a significant concern with overprescribing and occurs where the prescribing of multiple medicines is either inappropriate or where the intended benefit of the medication is not realised. Prescribing cascades contribute to problematic polypharmacy because they can lead to inappropriate medication use, adverse drug reactions, poor outcomes and increased healthcare resource use that could be avoided.

The publication aims to raise awareness of potential prescribing cascades and to highlight resources, tools, and strategies to help identify, prevent, and resolve inappropriate cascades.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.   

Monthly Horizon Scanning Report – February 2023

Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies. 

This information is produced for use by NHS healthcare professionals.